Burkholderiaceae abundance is associated with cognitive symptoms in women receiving chemotherapy for breast cancer: pilot results of the predict study


Courtney Subramaniam* 1, 2, Marc Gladman 1, Joanne Bowen 1, Hannah Wardill 1,2

School of Biomedicine, Adelaide Medical School, University of Adelaide, South Australia, Australia

1) Supportive Oncology Research Group, Precision Medicine (Cancer), South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, South Australia, Australia

Introduction


- Chemotherapy-induced cognitive impairment has been consistently identified as a priority concern by people living with and beyond cancer and is thought to develop due to neuroinflammatory processes¹
- The gut microbiota plays a pivotal role in shaping our immune system and neuroinflammation as well as cognitive symptom development in other diseases²
- Despite this, whether the microbiota plays a role in the development of chemotherapy-induced cognitive impairment remains unknown
 - Are there differences in microbiota composition in women with breast cancer, with and without cognitive impairment
- We aimed to characterise the gut microbiota composition during chemotherapy treatment and identify microbial features associated with cognitive symptoms




Acknowledgements & References

This research was funded by The Hospital Research Foundation Group and the National Health and Medical Research Council (NHMRC).

- 1. Santos & Pyter (2018). Front Immunol, vol.9
- 2. Cryan et al. (2019). Phsyiol Rev, vol.99(4)





Conclusions

Want to connect?

@CourtneyCross_1

Burkholderiaceae abundance is significantly associated with the severity of cognitive symptoms and diarrhoea burden, positioning this microbial family as a therapeutic target for both chemotherapy-induced gastrointestinal toxicity and cognitive impairment.



